MATERIALS AND METHODS

Cell lines
The human cell lines 293T and HeLa were maintained in Dulbecco's modified Eagles medium (DMEM) supplemented with 10% heated-inactivated fetal calf serum (Gibco, USA or Sijiqi, China). HeLa cell lines that stably express human ACE2 protein were established in a previous study (6) .
Plasmids and antibodies
Rabbit serum against inactivated SARS-CoV was kindly offered by Dr. Lin-Fa Wang at the Australian Animal Health Laboratory, CSIRO Livestock Industries.
AP-conjugated goat anti-rabbit IgG were purchased from PTGLab (Chicago, IL). Horseradish-peroxidaseconjugated protein G was obtained from PIERCE (Rockford, IL).
Bat sera
Bat sera were collected from the field as described previously (4).
Viral cDNA
The viral cDNA was prepared from SL-CoV positive bat fecal sample as described previously and used as template (4) . 
Western-blot analysis
Western-blot analysis was performed according to the standard protocol. Briefly, 100 ng of purified fusion protein was loaded into each well of a sodium dodecyl sulphate 12% polyacrylamide gel, then electroblotted onto a nitrocellulose membrane (PIERCE, USA). The membrane was incubated with rabbit serum against inactivated SARS-CoV (diluted at 1:1000), then bound with alkaline phosphatase-labbeld goat anti rabbit IgG. The result was detected by colorimetric assay using NBT/BCIP.
Indirect ELISA
The test was modified according to the standard protocol. Each well of the immunoplate (Jincanhua, Shenzhen) was coated with a series of concentrations of the purified (His) 6 To establish the baseline for the tests, sera from healthy bats were tested in this assay and the mean absorbance value (Nc) was calculated. The cut-off value was determined as 2.1×Nc. The sample was determined as positive when the absorbance value at 450 was greater than 2.1×Nc.
Cross Reaction between the SL-CoV N protein and sera from bat, mouse and rabbit
To evaluate the specificity of the indirect ELISA, sera from healthy bat, mouse and rabbit were tested according to the protocol described above. Sera were diluted at 1/100, 1/500 and 1/1000 respectively. The mean absorbance value for each dilution was calculated.
Seroprevalence of bat SL-CoV infections in bat populations
Using the protocol described above, we tested for the presence of IgG antibody against the bat SL-CoV N protein in bat serum samples. Rabbit serum against inactivated SARS-CoV and healthy bat serum was used as positive and negative control, respectively.
Pseudovirus-based neutralization assay
The construction of a codon-optimized full-length spike protein (S) gene of SARS-CoV BJ01 was prepared as described previously (6, (7). Due to a lack of permissive cell lines for bat SL-CoV, the sera neutralization assay to this virus was not conducted.
RESULTS
Expression and purification of the recombinant SL-CoV N protein
The N protein was successfully expressed in soluble solution in E. coli and purified. The size of the recombinant N protein was consistent with the expected size of 49.6 kDa (Fig. 1a) . Western-blot analysis confirmed that the expressed protein cross reacted with the rabbit serum against SARS-CoV (Fig. 1b) .
Specificity of indirect ELISA
Different concentrations of the recombinant N protein (1, 2, 10 µg/mL) were used as coated antigen to optimize the amount of coated antigen. The results showed that a concentration of 1 µg/mL is optimal for plate coating (data not shown). The results tested with sera from healthy bat, mouse and rabbit demonstrated that the purified SL-CoV N protein has no cross reactivity when the sera were diluted at 1:100 (data not shown).
Seroprevalence of the bat SL-CoV in bats
A total of 573 bat sera, collected during 2005-2008, were tested for presence of SL-CoV infections. As shown in Table 1 
